Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Impact · against what's priced in

Day One Biopharmaceuticals provides a positive outlook for 2026 with projected OJEMDA revenues between $225 million and $250 million and strong 2025 growth. These figures, combined with a healthy cash position of $441.1 million and pipeline expansion via Mersana, represent a significant positive catalyst for the company's valuation.

DAWN+0.70

No priced-in read yet